Table 1.
Clinico-pathologic characteristics of patients with advanced ovarian cancer, including HGSOC.
| Characteristics | All, n = 79 | HGSOC, n = 64 |
|---|---|---|
| Age | ||
| Median (range) | 56.3 (31–81.4) | 57.0 (31.0–81.4) |
| CA-125 at diagnosis U/mL | ||
| Median (range) | 855.3 (8.8–13100.0) | 832.8 (37.9–13100.0) |
| Tumor Histology | ||
| Serous | 64 (81.0) | 64 (100.0) |
| Endometrioid | 5 (6.3) | 0 (0.0) |
| Mixed | 3 (3.8) | 0 (0.0) |
| Undifferentiated | 2 (2.5) | 0 (0.0) |
| Mucinous | 1 (1.3) | 0 (0.0) |
| Transitional | 1 (1.3) | 0 (0.0) |
| Clear cells | 1 (1.3) | 0 (0.0) |
| Unclassified | 2 (2.5) | 0 (0.0) |
| FIGO Stage | ||
| IIIB | 3 (3.8) | 1 (1.6) |
| IIIC | 58 (73.4) | 50 (78.1) |
| IV | 18 (22.8) | 13 (20.3) |
| Tumor Grade a | ||
| G2 | 19 (24.0) | 18 (28.1) |
| G3 | 60 (76.0) | 46 (71.9) |
| RD at PDS | ||
| 0 | 40 (50.6) | 33 (51.6) |
| <1 cm | 39 (49.4) | 31 (48.4) |
| Lymph Node involvement | ||
| Negative | 15 (19.0) | 10 (15.6) |
| Positive | 42 (53.2) | 34 (53.1) |
| Unknown | 22 (27.8) | 20 (31.2) |
| Treatment | ||
| Carboplatin-Paclitaxel | 56 (70.9) | 45 (70.3) |
| Carboplatin-PDL | 11 (13.9) | 9 (14.1) |
| Carboplatin | 5 (6.3) | 5 (7.8) |
| Other b | 7 (8.9) | 5 (7.8) |
| PFI c, months | ||
| Median (range) | 8.8 (0.0–87.8) | 8.4 (0.0–87.8) |
| TTR c, months | ||
| Median (range) | 14.5 (4.6–93.6) | 14.5 (5.4–93.6) |
| Recurrence | 70 (88.6) | 56 (87.5) |
| OS, months | ||
| Median (range) | 47.7 (8.3–190.4) | 48.2 (13.5–190.4) |
| Deaths | 55 (69.6) | 42 (65.6) |
| Platinum sensitivity c | ||
| Refractory | 7 (8.9) | 3 (4.7) |
| Resistant | 14 (17.7) | 13 (20.3) |
| Intermediate | 20 (25.3) | 19 (29.7) |
| Sensitive | 36 (45.6) | 28 (43.7) |
a One patient with tumor grade G2–G3 was included in grade G3. b Other platinum-based treatments; c Two patients (one with HGSOC), were not evaluated due to loss at follow up. HGSOC: high-grade serous ovarian cancer. CA-125: Cancer Antigen 125; FIGO: Fédération Internationale de Ginécologie et d’Obstetrique; RD: residual disease; PDS: primary debulking surgery; PDL: Pegylated Liposomal Doxorubicin; PFI: platinum-free interval; TTR: time to recurrence; OS: overall survival; “platinum-refractory”: disease recurrence during treatment or within 4 weeks from the end of platinum treatment: “platinum-resistant”: disease recurrence within <6 months from the end of platinum treatment; “intermediately sensitive”: disease recurrence between 6 and 12 months from the end of platinum treatment; “platinum-sensitive”: disease recurrence >12 months from the end of platinum treatment.